Better Buy: AbbVie vs. Biogen

AbbVie (NYSE: ABBV) and Biogen (NASDAQ: BIIB) are two drugmakers that have moved in opposite directions on the stock market of late. While AbbVie has rebounded nicely from the market crash since late March -- with its stock up by 11.7% year to date as of this writing -- shares of Biogen have lost altitude since early April or so, and are down by 10.7% since the beginning of the year.

As we will see below, Biogen has encountered some severe headwinds recently, which explains its poor stock-price performance. There's a chance that the company could recover from its recent woes, but could it actually outperform AbbVie moving forward? Let's dig into these companies' businesses and see which of the two stocks is the better pick right now.